CBPLPharmaceuticals
Chandra Bhagat Pharma Ltd — Profit & Loss Statement
₹30.50
-4.77%
Chandra Bhagat Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.16 Cr | -0.46 Cr | — |
| Tax Rate For Calcs | 0.26 | 0.32 | 0.22 | 0.27 | — |
| Normalized EBITDA | 4.06 Cr | 4.29 Cr | 4.18 Cr | 5.79 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.73 Cr | -1.68 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.73 Cr | -1.68 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 0.86 Cr | 1.53 Cr | 0.91 Cr | 0.80 Cr | — |
| Reconciled Depreciation | 0.88 Cr | 0.49 Cr | 0.11 Cr | 0.04 Cr | — |
| Reconciled Cost Of Revenue | 73.28 Cr | 208.04 Cr | 106.67 Cr | 81.51 Cr | — |
| EBITDA | 4.06 Cr | 4.29 Cr | 3.45 Cr | 4.12 Cr | — |
| EBIT | 3.11 Cr | 3.65 Cr | 3.34 Cr | 4.08 Cr | — |
| Net Interest Income | -1.95 Cr | -1.39 Cr | -2.20 Cr | -3.08 Cr | — |
| Interest Expense | 1.95 Cr | 1.39 Cr | 2.17 Cr | 2.98 Cr | — |
| Normalized Income | 0.86 Cr | 1.53 Cr | 1.48 Cr | 2.02 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.86 Cr | 1.53 Cr | 0.91 Cr | 0.80 Cr | — |
| Total Expenses | 89.13 Cr | 229.06 Cr | 115.72 Cr | 88.67 Cr | — |
| Diluted NI Availto Com Stockholders | 0.86 Cr | 1.53 Cr | 0.91 Cr | 0.80 Cr | — |
| Net Income Common Stockholders | 0.86 Cr | 1.53 Cr | 0.91 Cr | 0.80 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.86 Cr | 1.53 Cr | 0.91 Cr | 0.80 Cr | — |
| Net Income Including Noncontrolling Interests | 0.86 Cr | 1.53 Cr | 0.91 Cr | 0.80 Cr | — |
| Net Income Continuous Operations | 0.86 Cr | 1.53 Cr | 0.91 Cr | 0.80 Cr | — |
| Tax Provision | 0.31 Cr | 0.73 Cr | 0.26 Cr | 0.30 Cr | — |
| Pretax Income | 1.17 Cr | 2.26 Cr | 1.16 Cr | 1.10 Cr | — |
| Other Non Operating Income Expenses | 5.52 Cr | 11.33 Cr | 0.20 Cr | 1.38 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.73 Cr | -1.68 Cr | — |
| Net Non Operating Interest Income Expense | -1.95 Cr | -1.39 Cr | -2.20 Cr | -3.08 Cr | — |
| Interest Expense Non Operating | 1.95 Cr | 1.39 Cr | 2.17 Cr | 2.98 Cr | — |
| Operating Income | -2.41 Cr | -7.68 Cr | 3.95 Cr | 5.40 Cr | — |
| Operating Expense | 15.85 Cr | 21.02 Cr | 9.06 Cr | 7.16 Cr | — |
| Other Operating Expenses | 12.38 Cr | 17.72 Cr | 3.09 Cr | 1.88 Cr | — |
| Depreciation And Amortization In Income Statement | 0.95 Cr | 0.64 Cr | 0.11 Cr | 0.04 Cr | — |
| Depreciation Income Statement | 0.95 Cr | 0.64 Cr | 0.11 Cr | 0.04 Cr | — |
| Gross Profit | 13.44 Cr | 13.34 Cr | 13.01 Cr | 12.56 Cr | — |
| Cost Of Revenue | 73.28 Cr | 208.04 Cr | 106.67 Cr | 81.51 Cr | — |
| Total Revenue | 86.72 Cr | 221.37 Cr | 119.67 Cr | 94.08 Cr | — |
| Operating Revenue | 86.72 Cr | 221.37 Cr | 119.67 Cr | 94.08 Cr | — |
| Interest Income | — | 67000.00 | 27000.00 | 0.15 Cr | 0.07 Cr |
| Rent Expense Supplemental | — | 0.06 Cr | 0.08 Cr | 0.10 Cr | 0.05 Cr |
| Diluted Average Shares | — | 0.75 Cr | 0.75 Cr | 0.75 Cr | 0.75 Cr |
| Basic Average Shares | — | 0.75 Cr | 0.75 Cr | 0.75 Cr | 0.75 Cr |
| Diluted EPS | — | 2.03 | 1.20 | 1.06 | 0.25 |
| Basic EPS | — | 2.03 | 1.20 | 1.06 | 0.25 |
| Write Off | — | -0.57 Cr | 0.73 Cr | 1.68 Cr | 0.02 Cr |
| Total Other Finance Cost | — | 0.10 Cr | 0.02 Cr | 0.25 Cr | 0.20 Cr |
| Interest Income Non Operating | — | 67000.00 | 27000.00 | 0.15 Cr | 0.07 Cr |
| Research And Development | — | 0.07 Cr | 0.07 Cr | 0.00 | — |
| Selling General And Administration | — | 8.97 Cr | 4.14 Cr | 3.44 Cr | 2.74 Cr |
| Selling And Marketing Expense | — | 6.24 Cr | 2.27 Cr | 1.95 Cr | 1.66 Cr |
| General And Administrative Expense | — | 2.73 Cr | 1.87 Cr | 1.48 Cr | 1.08 Cr |
| Rent And Landing Fees | — | 0.06 Cr | 0.08 Cr | 0.10 Cr | 0.05 Cr |
| Other Special Charges | — | — | — | — | 0.09 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Chandra Bhagat Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.